20/20 HealthCare Partners
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact

20/20 HealthCare Partners

01 Oct2015

Konica Minolta Acquires Viztek to Enhance Healthcare IT Solution Capabilities

Written by 2020HCP.com. Posted in News, Uncategorized

Wayne, NJ, October 1, 2015 – Konica Minolta, Inc. today announced the completed acquisition of Garner, North Carolina based Viztek, LLC, a leading innovative healthcare company, through Konica Minolta Medical Imaging. With this acquisition, Konica Minolta enhances its capabilities to offer comprehensive, end-to-end healthcare IT solutions from image acquisition to physician diagnosis. It also adds to the established strength
  • Continue Reading
09 Oct2014

20/20 HCP Investment Goes Public: VBL Therapeutics Announces Closing of Initial Public Offering

Written by 2020HCP.com. Posted in Uncategorized

TEL AVIV, Israel, Oct. 6, 2014 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the closing of its initial public offering of 6,666,667 shares of its common stock at a public offering price of $6.00 share, before underwriting discounts and commissions. As a result, aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $34.4 million. As previously reported, VBL Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 ordinary shares to cover over-allotments, if any, at the initial public offering price, before underwriting discounts and commissions. The proceeds from the offering are expected to enable the advancement of the company’s development plan in both its Vascular Targeting System® and Lecinoxoid platform technologies through the end of 2016. A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on September 30, 2014. Deutsche Bank Securities is acting as book-running manager for the offering. JMP Securities and Oppenheimer & Co. are acting as co-managers. The offering is being made only by means of a prospectus, copies of which may be obtained from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, New York 10005-2836, or by calling (800) 503-4611 or emailing a request to prospectus.cpdg@db.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. About VBL: Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics’ clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body’s natural physiologic and genetic regulatory elements. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the single needed Phase 3 pivotal trial for VB-111 in rGBM in the first half of 2015 under a SPA whose design and planned analysis the FDA concurred with. VBL Therapeutics’ lead product candidate from its anti-inflammatory program, VB-201, is an oral small molecule currently being evaluated in Phase 2 clinical trials for psoriasis and for ulcerative colitis, with top-line results expected in the first quarter of 2015.
  • Continue Reading
22 May2014

Massachusetts Life Sciences Center Announces New Appointee to Board of Directors and Four New Members of Scientific Advisory Board

Written by 2020HCP.com. Posted in Uncategorized

The Massachusetts Life Sciences Center (MLSC) announced today that Governor Deval Patrick has appointed Adelene Perkins, Chair, President and Chief Executive Officer of Infinity Pharmaceuticals, Inc. to the MLSC Board of Directors. Additionally, the MLSC Scientific Advisory Board (SAB) is welcoming four new members, including Frederick J. Schoen, M.D., Ph.D., Hillel Bachrach, Frederick Jones, M.D., and Alison F. Lawton. The MLSC’s seven member Board of Directors, appointed by the Governor and co-chaired by Secretaries Gregory Bialecki (Housing and Economic Development) and Glen Shor (Administration and Finance), oversees the agency’s operations and programs. The SAB, chaired by Dr. Harvey F. Lodish, Member of the Whitehead Institute for Biomedical Research and Professor of Biology and Professor of Bioengineering at Massachusetts Institute of Technology, advises the Center on investment decisions and program development. Through the MLSC, Massachusetts is investing $1 billion over 10 years in the growth of the state’s life sciences ecosystem. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Deval Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008. “Adelene Perkins is a leader in our state’s thriving Life Sciences community, and she will be a terrific addition to the Life Sciences Center’s Board of Directors,” said Governor Patrick. “The Commonwealth is fortunate to have her talent, as well as the talents of these four well-qualified new SAB members, at the table to help guide the Center’s investment decisions as we continue the successful implementation of the Massachusetts Life Sciences Initiative.” Ms. Perkins has served as Infinity’s president and chief executive officer since 2009 and as board chair since 2012. Ms. Perkins first joined Infinity as chief business officer in 2002 and was named president in 2008. She has played an integral role in leading the company, guiding its transition from a platform to a product-focused organization, building the team and forming strategic partnerships to advance the company’s product pipeline and establish a strong financial foundation. Ms. Perkins has more than 25 years of international business experience in the biopharmaceutical industry, focused on building and leading high-caliber, cross-functional teams, corporate strategy, licensing and business development, strategic finance, and product life cycle management. Prior to Infinity, she held leadership positions at TransForm Pharmaceuticals, Genetics Institute and Bain & Company. Ms. Perkins will fill the seventh seat on the board. Other Board members include President and CEO of Dana-Farber Cancer Institute Edward J. Benz Jr., M.D., Founder and CEO (retired) of Vertex Pharmaceuticals, Josh Boger, Ph.D, President of The University of Massachusetts, Robert L. Caret, Ph.D and Director and Chief Scientific Officer of Cytonome/ST, Lydia Villa-Komaroff, Ph.D. “Massachusetts has become the global leader in life sciences through initiatives that bring together our thriving medical, academic, industry and government communities,” stated Ms. Perkins. “The Massachusetts Life Sciences Center fosters and extends this collaborative environment, bringing together public and private organizations from around the world to propel innovation, create jobs and advance human health and well-being. I look forward to working with the Board and leaders at the Center in advancing its important mission.” “We are so pleased to welcome Adelene Perkins as the newest member of our Board of Directors,” said Susan Windham-Bannister, Ph.D., President & CEO of the MLSC. “The Board is the final arbiter of all of our major investments decisions, so we rely on these experts to ensure that the Center is making the best use of the public dollars that are under our stewardship. We greatly appreciate Adelene’s willingness to add her strong industry knowledge and background to the leadership of the Life Sciences Initiative. ” Profiles and quotes for new SAB members: Frederick J. Schoen, M.D., Ph.D., is a Professor of Pathology and Health Sciences and Technology at Harvard Medical School. He is also the Executive Vice-Chairman for the Department of Pathology at Brigham and Women’s Hospital (BWH) and the Director of the BWH Biomedical Research Institute Technology Innovation Program. Schoen has extensive experience in preclinical and clinical development and evaluation of heart valve substitutes and other medical devices, translational innovation, and academic-corporate collaboration. “I am most enthusiastic to join the SAB and thereby contribute to the selection of strategic opportunities that leverage public investment in Massachusetts’ life sciences sector, and help maintain the strong legacy of effective collaborative, economic growth stimulation and job creation established by the MLSC since its inception,” said Schoen. Hillel Bachrach joins the Scientific Advisory Board with over 30 years of hands-on experience as an entrepreneur, as well as great success in innovative medical technologies. Bachrach is the managing partner of 20/20 HealthCare Partners LLC. Previous work includes co-founding ESC Medical, (now Lumenis), Msq, (now Alma Lasers) and Orex Computed Radiography. He is now the active Chairman of Viztek & UltraSPECT and on the BOD of: Corindus, SRS as well as other healthcare and hi-tech companies also funded by 20/20 HealthCare Partners. “I am thrilled to join the SAB and be part of the MLSC’s mission and vision. I look forward to working with other SAB members and serving the Commonwealth,” said Hillel Bachrach. Frederick “Rick” Jones, M.D., manages day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure and portfolio company board involvement. Previously, Rick founded Spordiff Therapeutics. Rick was also the CEO of Anchor Therapeutics after leadership positions in management, business development and medical affairs at several biotech and pharma companies. Rick began his career practicing internal medicine. ”I look forward to bringing my broad background to assist the MLSC in its mission to support Massachusetts biotech companies and maintain the state’s leadership in the industry,” said Frederick Jones, M.D.. Alison Lawton has been involved in the global pharmaceutical and biotechnology world for 29 years. Her background includes 21 years at Genzyme Corporation as well as seven years in the U.K. at Warner-Lambert/Parke-Davis. Most recently, Lawton was COO of OvaScience. Previously, Lawton has served as the Senior Vice President and General Manager of Sanofi Biosurgery. and as Senior Vice President of Global Market Access for Genzyme. Lawton currently serves on the board of directors for Cubist Pharmaceuticals and Verastem Inc. “MLSC is an important organization promoting life sciences innovation in Massachusetts and I am delighted to be part of this by participating on the SAB ,” said Alison Lawton. “Our Scientific Advisory Board members play a critical role in the Center’s review processes and investment decisions” said Susan Windham-Bannister, Ph.D., President & CEO of the MLSC. “SAB members are experts from the life sciences industry, the investment community and academia, and their diverse perspectives help ensure that the Center is making the best use of public dollars. We are excited and grateful that these four experts are willing to contribute their time, talent and expertise.”
  • Continue Reading

Latest News

  • Variantyx Secures $20M Debt Financing to Support Precision Medicine in North America, Europe October 18, 2022
  • SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting June 21, 2022
  • SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors April 28, 2022
  • SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo April 11, 2022
  • SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes April 5, 2022

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact